<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670823</url>
  </required_header>
  <id_info>
    <org_study_id>ELM-55 5323-18-SMC</org_study_id>
    <nct_id>NCT03670823</nct_id>
  </id_info>
  <brief_title>Prediction of SSRI Treatment in Major Depression.</brief_title>
  <official_title>A Combination of Innovative Technologies: EEG, Eye Tracking Device and fMRI in Order to Predict the Success of SSRI Treatment in Patients With Major Depression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ElMindA Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebrew University of Jerusalem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ElMindA Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will combine the data collected from EEG, Eye tracking, structural and
      functional MRI scans and neuropsychological performance from patients with major depression
      receiving SSRI treatment. The purpose of this research is to predict the success of the SSRI
      treatment and to categorize patients into sub-groups according to similar patterns of brain
      activation to personalize treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depression is a mood disorder affecting 350 million people worldwide. The disorder is
      characterized by depressed mood, anhedonia, decreased quality of life, deficits in cognitive
      functions and even suicide thoughts. Treatment of depression is often a long process and
      includes taking different types and quantities of medications. Therefore, there is a need to
      predict the success of the SSRI treatment. Our research will examine the outcomes of the
      combined technologies: BNA (EEG), Eye-tracker, structural and functional MRI scans and
      neuropsychology tasks in patients with depression while receiving SSRI treatment. The purpose
      of the research is to track biomarkers and other measures, which will allow predicting the
      SSRI treatment's success within 4 weeks instead of 8 weeks. In addition, the investigators
      will attempt to categorize patients into different subgroups according to their brain
      activation and eye movements. This division into subgroups may contribute to the
      understanding of the mechanisms that account for the responsiveness to SSRI treatment and to
      the possibility of targeting patients with depression towards a particular treatment. From
      this research, the investigators aim to personalize the treatment of depression, make it more
      efficient and reduce the amount of time for the patient to reach an optimal responsiveness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EEG responses to cognitive tasks in combination with the Eye-tracker Device.</measure>
    <time_frame>2 years</time_frame>
    <description>Categorize patients into subgroups according to combined measures of EEG and Eye</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting state connectivity analysis</measure>
    <time_frame>2 years</time_frame>
    <description>Examine the difference in resting state connectivity between the groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine correlations between the different methods</measure>
    <time_frame>2 years</time_frame>
    <description>Examine correlations between the different methods EEG, Eye-tracking and fMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EEG brain activation to cognitive tasks</measure>
    <time_frame>2 years</time_frame>
    <description>Categorize patients into subgroups according to similar brain activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye-tracking tasks</measure>
    <time_frame>2 years</time_frame>
    <description>Categorize patients into subgroups according to similar patterns of eye movements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine MRI structural changes</measure>
    <time_frame>2 years</time_frame>
    <description>Compare structural changes between the groups (patients with depression, healthy subjects).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive scores on CANTAB (computerized cognitive assessments)</measure>
    <time_frame>2 years</time_frame>
    <description>Examine the difference in responses to different cognitive exams between the groups</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>50 healthy subjects for a control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Major Depression</arm_group_label>
    <description>50 patients with major depression for a research group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SIEMENS PRISMA MRI</intervention_name>
    <description>Collect data on brain activation from different methods</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patients with Major Depression</arm_group_label>
    <other_name>BNA (EEG) Technology, Eyetracking device</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population will include 2 groups of subjects: healthy subjects and patients with
        major depression
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18-65 years old

          2. Male and female

          3. Ability to comprehend and sign informed consent

          4. DSM-5 diagnosis with MINI 7.0.2 (healthy subjects need to be ruled out)

        Inclusion Criteria for patients with depression:

          1. DSM-5 diagnosis

          2. 0-2 failed treatments

          3. Patients which will start SSRI treatment

        Exclusion Criteria:

          1. unconsciousness

          2. Pregnancy or nursing

          3. Cardiovascular instability

          4. Metabolic instability (water, electrolytes, sugar)

          5. Fever or evidence of microbiological pollutant

          6. Deafness or blindness

          7. Schizophrenia

          8. Addiction disorders

          9. Eating disorders

         10. Bi-polar disorder

         11. Cognitive deficits

         12. Start a new psychotherapy during the research

         13. Unable to enter the MRI scanner
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Revital Amiaz</last_name>
    <phone>+972505250590</phone>
    <email>Revital.Amiaz@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liran Korine</last_name>
    <phone>+972507453300</phone>
    <email>liran@elminda.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical CENTER</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarel Shlomo</last_name>
      <phone>03-5303075</phone>
      <email>nivdakim.sheba@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, Fetcho RN, Zebley B, Oathes DJ, Etkin A, Schatzberg AF, Sudheimer K, Keller J, Mayberg HS, Gunning FM, Alexopoulos GS, Fox MD, Pascual-Leone A, Voss HU, Casey BJ, Dubin MJ, Liston C. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017 Jan;23(1):28-38. doi: 10.1038/nm.4246. Epub 2016 Dec 5. Erratum in: Nat Med. 2017 Feb 7;23 (2):264.</citation>
    <PMID>27918562</PMID>
  </reference>
  <reference>
    <citation>Ogawa T, Sekino H, Uzura M, Sakamoto T, Taguchi Y, Yamaguchi Y, Hayashi T, Yamanaka I, Oohama N, Imaki S. Comparative study of magnetic resonance and CT scan imaging in cases of severe head injury. Acta Neurochir Suppl (Wien). 1992;55:8-10.</citation>
    <PMID>1414552</PMID>
  </reference>
  <reference>
    <citation>Raichle ME, Snyder AZ. A default mode of brain function: a brief history of an evolving idea. Neuroimage. 2007 Oct 1;37(4):1083-90; discussion 1097-9. Epub 2007 Mar 6. Review.</citation>
    <PMID>17719799</PMID>
  </reference>
  <reference>
    <citation>Rohden AI, Benchaya MC, Camargo RS, Moreira TC, Barros HMT, Ferigolo M. Dropout Prevalence and Associated Factors in Randomized Clinical Trials of Adolescents Treated for Depression: Systematic Review and Meta-analysis. Clin Ther. 2017 May;39(5):971-992.e4. doi: 10.1016/j.clinthera.2017.03.017. Epub 2017 May 2. Review.</citation>
    <PMID>28476404</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depression</keyword>
  <keyword>EEG</keyword>
  <keyword>Eye Tracker</keyword>
  <keyword>fMRI</keyword>
  <keyword>MRI</keyword>
  <keyword>Resting State Connectivity</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

